Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Inventory (2016 - 2025)

Historic Inventory for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $629.1 million.

  • Dexcom's Inventory rose 1594.18% to $629.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $629.1 million, marking a year-over-year increase of 1594.18%. This contributed to the annual value of $629.1 million for FY2025, which is 1594.18% up from last year.
  • Dexcom's Inventory amounted to $629.1 million in Q4 2025, which was up 1594.18% from $604.1 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Inventory registered a high of $629.1 million during Q4 2025, and its lowest value of $289.7 million during Q1 2021.
  • For the 5-year period, Dexcom's Inventory averaged around $454.6 million, with its median value being $459.8 million (2023).
  • Per our database at Business Quant, Dexcom's Inventory skyrocketed by 10415.79% in 2021 and then plummeted by 1416.18% in 2022.
  • Over the past 5 years, Dexcom's Inventory (Quarter) stood at $357.3 million in 2021, then dropped by 14.16% to $306.7 million in 2022, then soared by 82.46% to $559.6 million in 2023, then decreased by 3.04% to $542.6 million in 2024, then rose by 15.94% to $629.1 million in 2025.
  • Its Inventory was $629.1 million in Q4 2025, compared to $604.1 million in Q3 2025 and $570.7 million in Q2 2025.